Skip to main content
. Author manuscript; available in PMC: 2017 Jul 5.
Published in final edited form as: Cancer Genet. 2016 Apr 5;209(5):182–194. doi: 10.1016/j.cancergen.2016.03.004

Figure 1.

Figure 1

Percent of Ewing sarcoma with EWS/ETS translocations, STAG2 loss, TP53 abnormalities, and CDKN2A deletions. Adapted from Brohl, et al, PLoS Genet. 2014, Crompton, Stewart, et al, Cancer Discov. 2014, and Tirode, et al, Cancer Discov. 2014[30–32].